Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development - Wikidata - awgldk - TriplyDB

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

http://www.wikidata.org/entity/Q27649767

about

Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases High-resolution structures ofTrypanosoma bruceipteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target Structure of recombinantLeishmania donovanipteridine reductase reveals a disordered active site The crystal structure of Leishmania major N5,N10-methylenetetrahydrofolate dehydrogenase/cyclohydrolase and assessment of a potential drug target Structure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1 The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations Metabolic signatures of triatomine vectors of Trypanosoma cruzi unveiled by metabolomics Transcriptome Remodeling in Trypanosoma cruzi and Human Cells during Intracellular Infection Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice In silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis.TRAPP webserver: predicting protein binding site flexibility and detecting transient binding pockets.Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1.LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania LmABCB3, an atypical mitochondrial ABC transporter essential for Leishmania major virulence, acts in heme and cytosolic iron/sulfur clusters biogenesis.Methylene tetrahydrofolate dehydrogenase/cyclohydrolase and the synthesis of 10-CHO-THF are essential in Leishmania major.Ursolic Acid, a Natural Pentacylcic Triterpene from Ochrosia elliptica and Its Role in The Management of Certain Neglected Tropical Diseases.Folate metabolic pathways in Leishmania Genomic organization of leishmania species.Pteridine-2,4-diamine derivatives as radical scavengers and inhibitors of lipoxygenase that can possess anti-inflammatory properties.In-silico analyses of sesquiterpene-related compounds on selected Leishmania enzyme-based targets.In-silico Leishmania target selectivity of antiparasitic terpenoids.Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis.Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.Pterin-sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents.Application of a simple quantum chemical approach to ligand fragment scoring for Trypanosoma brucei pteridine reductase 1 inhibition.Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery.Molecular cloning, expression and enzymatic assay of pteridine reductase 1 from Iranian lizard Leishmania.Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information.Genetically Validated Drug Targets in Leishmania; Current Knowledge and Future Prospects.Silver-catalyzed decarboxylative acylation of quinoxalin-2(1H)-ones with α-oxo-carboxylic acids.Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity.3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors.Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis

P2860

Q27011766-8514443F-7E8E-4874-B3C5-E49DF227FB79 Q27655956-BD57C940-1EC3-4B43-9681-634E18DF85FD Q27658197-0B776D8D-2A1E-4446-8C1F-8A8130EED9EE Q27666140-BDF0716E-D839-4131-BF95-30BEAE55AB3E Q27666482-2990AC5C-EBE3-4DD0-82B5-79D40DA31572 Q27675760-05629FC4-A637-4DF9-93DD-E238E741924E Q27684633-7F1999BF-6B02-4EA0-8473-30041D8A2782 Q28066944-4ED9558B-FCB1-468E-9614-F063A98B241C Q28534750-5DC76BDE-AA65-43BA-BE86-1C57F24F041E Q28551174-A8BF44CD-C63B-42FF-86E9-11A627A4F3D2 Q34044853-12D5C896-957D-4B95-A946-02D36FC7D326 Q34528982-C23C3407-EF7C-4481-90FE-EE57B08E2D80 Q34555623-078D858C-A34A-4D8C-B0CB-96F42E3CD072 Q34619406-31135A82-24D4-4EB7-9A21-F5862FB736EC Q34702464-93E9CEB1-80D9-4DA1-A640-1C4626703650 Q36428337-A14BC875-2675-43E9-8815-B4242540E662 Q37217438-F2019BEA-2C9F-47F1-958C-021772313C15 Q37394710-A561406D-5E33-4A70-B936-D269326973C3 Q37948934-0DE09877-86F5-448A-BA9F-2B95FB74CCBD Q37985972-6B202281-39B8-4982-96F3-F0B8599439C6 Q38958116-D4DA7541-EC66-4F53-9F80-160511C6B073 Q39200387-7854D72D-CD40-4331-AD41-FFCF5C4E0322 Q39318097-D47F961E-13BF-4AC1-AA43-E4B0E643E2D1 Q39328997-9F1830CE-3E41-49BA-9B91-56464BAE6540 Q39386461-EAABAD26-6443-49E2-BE3C-24E864E6D35E Q41365032-7B518260-14F9-4F8F-96D8-F6B546C7C1C4 Q41515537-801C9FCC-AA20-4CEF-B8DD-E8443F843C5D Q42163449-57D1027B-A89A-4D72-A343-F68FF2965A74 Q42732972-4A3BAC2E-5C85-4B77-B4FF-DED35F3E0E22 Q43046133-4BB91E71-1960-480D-95E3-F5D145BBB8DC Q45213048-8DAFED5A-E28D-43CB-8D10-5DBC4E719BA4 Q47702679-836D70B1-DC7C-46B8-9F5F-AA171C19FCD2 Q50078850-E6EC4DCD-805A-4925-8C9B-90DF721E13C5 Q51102354-B7FFE0E6-2B10-4C28-943B-6A5AD7B97AC2 Q51541343-11518551-A477-40F5-B5A4-8CC229EC6ADD Q57190987-3198FFF7-771C-402D-8CFE-A925E7B8E9AA

P2860

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

http://www.wikidata.org/entity/Q27649767

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@ast

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@en

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@nl

type

label

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@ast

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@en

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@nl

prefLabel

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@ast

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@en

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@nl

P1433

Q27649767-444DD6A2-48F7-47B1-ABAB-86984FFEF6FD

P1476

Q27649767-3E468142-A64A-4D92-BA71-99F48D9CF8A4

P2093

Q27649767-17DB4FE3-A15A-44AE-B0C8-0AC3C4277C4B

Q27649767-3807B926-BAFC-492B-B9C3-BE9F98859E83

Q27649767-58B46653-982E-4DF2-859C-4F26ADF64A09

Q27649767-88555793-9A59-4E6F-BF68-DDE80B51FAB7

Q27649767-AB00A3CD-0A46-4602-B676-65EAC68E0F7E

Q27649767-B86FF44F-C6F7-487C-858B-E9276E0371F5

Q27649767-BDFC2AC9-AF01-44B6-9168-401599A815E8

Q27649767-C11D320F-4560-457A-ACB7-F80BF460B384

P2860

Q27649767-064A1B79-EB6D-425F-949B-13D96DE85C83

Q27649767-1BDE2006-3C87-4E5F-8022-9CD25F787A11

Q27649767-272847A9-98EE-4DEA-93C5-DA07C5841547

Q27649767-2FCB5095-92C1-4875-B23B-7128A6F7300D

Q27649767-3ACB6C74-4D44-48CD-9D2C-0BC9A3B34544

Q27649767-43B3033E-C177-42FB-A386-75B796CF52CC

Q27649767-44B14BAC-E61B-4D7B-99A7-FF766539C93B

Q27649767-512BF19A-A862-499C-BE90-8ADC287461C1

Q27649767-57C4CE55-6C16-46DF-8C7F-1F5E0DAA1344

Q27649767-65300498-2519-4360-AAEA-7E37FC7838EF

P304

Q27649767-F4002510-6E82-47AA-9F6B-906ED39283EE

P31

Q27649767-65D64448-B680-433C-BC18-512B59939521

P3181

Q27649767-06F3141C-D285-4AA6-935C-7F500C735830

P356

Q27649767-9497C6D2-980F-4702-98CB-CB6EE96A6234

P407

Q27649767-8EC9C6DA-81A7-409D-B4D8-6A2A77CC9750

P433

Q27649767-5FFAE0F4-B0E6-4958-BDA4-107EFE630A2D

P478

Q27649767-38311A26-C20B-44AC-8245-40B988CE0362

P50

Q27649767-269EDF23-6EBB-429F-ACA8-0C7BCEAA7D2C

Q27649767-5CC89643-D4C2-44D8-A2EC-E6FC77FB6C7D

Q27649767-9A3CE20D-6C23-41AE-A31B-A4F63C18E988

Q27649767-BEFCDF00-F643-4E68-8E6E-C1E5856F08F6

Q27649767-D9AD4621-4154-4B74-9096-EFB15E751132

P577

Q27649767-477E2400-D2FA-4F74-AF03-C80D277BD94A

P5875

Q27649767-3F4A2114-18AE-4779-96A5-0B6DB6C34F66

P698

Q27649767-628981C3-69F7-423D-825D-2A489C59CBF9

P932

Q27649767-0FA7C7AE-A053-4D02-9B3D-AC17E624D9C5

P3181

P356

PNAS.0704384105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

@en

P2093

Antonio Cavazzuti

http://www.w3.org/2001/XMLSchema#string

Federica Gibellini

http://www.w3.org/2001/XMLSchema#string

Giuseppe Paglietti

http://www.w3.org/2001/XMLSchema#string

Karen McLuskey

http://www.w3.org/2001/XMLSchema#string

Mario Loriga

http://www.w3.org/2001/XMLSchema#string

Paola Corona

http://www.w3.org/2001/XMLSchema#string

Sandra Piras

http://www.w3.org/2001/XMLSchema#string

Sergio Allecca

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites

Studies on transformation of Escherichia coli with plasmids

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Anticancer antifolates: current status and future directions

Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.

Antimicrobial dihydrofolate reductase inhibitors--achievements and future options: review.

PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major.

Mechanisms of resistance of malaria parasites to antifolates.

Thymidylate synthase structure, function and implication in drug discovery.

P304

1448-1453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2481441

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0704384105

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Stefania Ferrari

Maria Paola Costi

Lindsay Tulloch

Francisco Gamarro

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5607574

http://www.w3.org/2001/XMLSchema#string

P698

18245389

http://www.w3.org/2001/XMLSchema#string

P932

2234164

http://www.w3.org/2001/XMLSchema#string